Older adults with myelodysplastic syndrome can benefit from transplants

Key clinical point: Overall survival improved by more than 20% in older adults with myelodysplastic syndrome who received allogeneic stem cell transplantation.

Major finding: Overall survival at 3 years was 47.9% for patients who received allogeneic hematopoietic cell transplantation compared to those who did not.

Study details: The data come from myelodysplastic syndrome patients with a median age of 66 years who were part of the prospective Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study 1102 (NCT02016781) presented at the American Society of Hematology (ASH) 2020 virtual meeting.

Disclosures: Lead author Dr. Cutler disclosed serving as a consultant for Mesoblast, Generon, Medsenic, Jazz, Kadmon, and Incyte.

Source: Cutler C et al. ASH 2020.

Key clinical point: Overall survival improved by more than 20% in older adults with myelodysplastic syndrome who received allogeneic stem cell transplantation.

Major finding: Overall survival at 3 years was 47.9% for patients who received allogeneic hematopoietic cell transplantation compared to those who did not.

Study details: The data come from myelodysplastic syndrome patients with a median age of 66 years who were part of the prospective Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study 1102 (NCT02016781) presented at the American Society of Hematology (ASH) 2020 virtual meeting.

Disclosures: Lead author Dr. Cutler disclosed serving as a consultant for Mesoblast, Generon, Medsenic, Jazz, Kadmon, and Incyte.

Source: Cutler C et al. ASH 2020.

Key clinical point: Overall survival improved by more than 20% in older adults with myelodysplastic syndrome who received allogeneic stem cell transplantation.

Major finding: Overall survival at 3 years was 47.9% for patients who received allogeneic hematopoietic cell transplantation compared to those who did not.

Study details: The data come from myelodysplastic syndrome patients with a median age of 66 years who were part of the prospective Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study 1102 (NCT02016781) presented at the American Society of Hematology (ASH) 2020 virtual meeting.

Disclosures: Lead author Dr. Cutler disclosed serving as a consultant for Mesoblast, Generon, Medsenic, Jazz, Kadmon, and Incyte.

Source: Cutler C et al. ASH 2020.